knowledge -WSS

knowledge

author：focus 2025-09-29 22:47:32 - browse：65773

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Readout Newsletter: Bayer study halts, Carmot to IPO, and more

hotspot

WSS

STAT Readout: Friday, Oct. 20 biotech updates

STAT Readout Newsletter: Biotech news today

Hospitals look to new technology to keep health care workers safe

UnitedHealth, Optum discontinue NaviHealth name

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Results on Novartis prostate cancer therapy could expand its use

focus

knowledge

entertainment

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

STAT Summit: Ending the crisis of Black deaths in the U.S.

Bright Health sells Medicare Advantage business to Molina

The problems with dementia villages

After affirmative action ruling, medical educators look to 'holistic review'

Hospitals look to new technology to keep health care workers safe

Continuity nursing helped my family in our darkest PICU moments

Weight loss drug costs may need more research, senator suggests

Supreme Court strikes down use of affirmative action

Gain of function research would be limited under House proposal

knowledge

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

STAT Summit: How researchers deal with rejection

Childhood cancer progress stalls for Black, Hispanic kids: Report

Does good food count as health care? Study aims to find out

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Roivant's CEO is a star, but biotech's black hole persists

focus

explore

hotspot

knowledge